Trial Profile

CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene After Haploidentical Stem Cell Transplantation

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 06 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rivogenlecleucel (Primary) ; Rimiducid
Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
Acronyms CASPALLO

01 Jul 2026 Planned End Date changed from 1 Jul 2026 to 1 Jul 2027.
11 Apr 2018 According to a Bellicum Pharmaceuticals media release, status changed from suspended to active, no longer recruiting.
11 Apr 2018 According to a Bellicum Pharmaceuticals media release, the company announces the U.S. Food and Drug Administration has lifted the clinical hold on studies of BPX-501 in the U.S. and will be working with U.S. clinical sites to resume patient recruitment based on the amended protocols.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com